Financial reports
10-K/A
2023 FY
Annual report (amended)
17 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
29 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
11 May 22
10-K
2021 FY
Annual report
23 Mar 22
Current reports
8-K
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
28 Mar 24
8-K
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
19 Mar 24
8-K
Termination of a Material Definitive Agreement
1 Mar 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates
4 Jan 24
8-K
Termination of a Material Definitive Agreement
21 Dec 23
8-K
Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A
6 Dec 23
8-K
Regulation FD Disclosure
4 Dec 23
8-K
Regulation FD Disclosure
29 Nov 23
8-K
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
13 Nov 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
15 Jun 23
S-3/A
Shelf registration (amended)
24 May 23
S-3
Shelf registration
12 May 23
424B5
Prospectus supplement for primary offering
5 May 21
424B5
Prospectus supplement for primary offering
27 Aug 20
424B5
Prospectus supplement for primary offering
26 Aug 20
424B5
Prospectus supplement for primary offering
1 Jul 20
S-3/A
Shelf registration (amended)
4 May 20
S-3
Shelf registration
17 Apr 20
424B5
Prospectus supplement for primary offering
10 Mar 20
Proxies
PRE 14A
Preliminary proxy
26 Apr 24
DEF 14A
Definitive proxy
28 Apr 23
DEF 14A
Definitive proxy
11 Apr 22
PRE 14A
Preliminary proxy
1 Apr 22
DEFA14A
Additional proxy soliciting materials
7 Jun 21
DEFA14A
Additional proxy soliciting materials
1 Jun 21
DEFA14A
Additional proxy soliciting materials
28 May 21
DEFA14A
Additional proxy soliciting materials
26 Apr 21
DEF 14A
Definitive proxy
26 Apr 21
PRE 14A
Preliminary proxy
16 Apr 21
Other
EFFECT
Notice of effectiveness
30 May 23
CORRESP
Correspondence with SEC
24 May 23
UPLOAD
Letter from SEC
19 May 23
EFFECT
Notice of effectiveness
14 May 20
CORRESP
Correspondence with SEC
12 May 20
CORRESP
Correspondence with SEC
11 May 20
CORRESP
Correspondence with SEC
4 May 20
UPLOAD
Letter from SEC
27 Apr 20
EFFECT
Notice of effectiveness
23 May 19
CORRESP
Correspondence with SEC
20 May 19
Ownership